Prostate cancer and solid organ transplantation: patient management and outcomes
BJU International · 2025-02 · 135 (2) · 339-345
DOI: 10.1111/bju.16558 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift BJU International, online erschienen am 09.10.2024. Verfasst von Alon Lazarovich und 8 weiteren Autor:innen. Beteiligte Einrichtung: Section of Urology, Department of Surgery, University of Chicago, Chicago, IL, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Organ Transplantation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To analyse the management and outcomes of individuals diagnosed with prostate cancer either before or after organ transplantation, as the impact of organ transplantation and associated immunosuppression on the incidence, progression, and mortality of prostate cancer remains an area of substantial clinical interest and uncertainty. Patients and Methods We conducted a retrospective analysis of patients from two tertiary care centres who had solid organ transplantation and were diagnosed with prostate cancer before or after organ transplantation. Data collected included demographics and clinical information.
Results
The cohort consisted of 110 patients with a median (interquartile range [IQR]) age at prostate cancer diagnosis of 62 (56.6–67.2) years and a median (IQR) age at transplantation of 58.6 (52.7–65.3) years. Renal transplantation was the most common (54%). The median (IQR) prostate‐specific antigen concentration at prostate cancer diagnosis was 6.2 (4.5–10) ng/mL, and the distribution of American Urological Association risk groups was: low risk, 36%; intermediate risk, 50%; and high risk, 14%. In all, 45 (41%) patients were diagnosed with prostate cancer prior to transplantation. Management included radical prostatectomy (RP; 62%), prostate radiotherapy (RT; 13%), and active surveillance (AS; 18%). During a median (IQR) follow‐up of 5.8 (2.5–10) years from prostate cancer diagnosis, one (2%) patient developed metastatic disease. In all, 65 (59%) patients were diagnosed with prostate cancer subsequent to organ transplantation. Management included AS (29%), RT (45%), and RP (15%). During a median (IQR) follow‐up of 5.3 (1–8.4) years, three patients (5%) developed metastatic disease. There were no deaths from prostate cancer.
Conclusion
A diagnosis of localised prostate cancer should not preclude solid organ transplantation, and the presence of a transplant does not appear to substantially impact risk of prostate cancer progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Urology, Department of Surgery, University of Chicago, Chicago, IL, USA.
- Department of Urology, University of Michigan, Ann-Arbor, MI, USA.
- Section of Nephrology, Department of Medicine, University of Chicago, Chicago, IL, USA.
- Section of Transplant Surgery, Department of Surgery, University of Chicago, Chicago, IL, USA.
- Department of Urology and Transplant Surgery, AP-HP, Université de Paris/Hôpital Européen Georges-Pompidou, Paris, France.
ORCID-Profile: Alon Lazarovich, Michelle A Josephson
Zitieren
APA
Lazarovich, A., Kristof, T. W., Steadman, S., Dahmen, A. S., Josephson, M. A., Barth, R., Morgan, T. M., Timsit, M. O., & Eggener, S. (2025). Prostate cancer and solid organ transplantation: patient management and outcomes. BJU International, 135(2), 339-345. https://doi.org/10.1111/bju.16558
Vancouver
Lazarovich A, Kristof TW, Steadman S, Dahmen AS, Josephson MA, Barth R, et al. Prostate cancer and solid organ transplantation: patient management and outcomes. BJU International. 2025;135(2):339-345. doi:10.1111/bju.16558
BibTeX
@article{Lazarovich2025,
author = {Lazarovich, Alon and Kristof, Tanya W and Steadman, Shavano and Dahmen, Aaron S and Josephson, Michelle A and Barth, Rolf and Morgan, Todd M and Timsit, Marc-Olivier and Eggener, Scott},
title = {Prostate cancer and solid organ transplantation: patient management and outcomes},
journal = {BJU International},
year = {2025},
volume = {135},
number = {2},
pages = {339--345},
doi = {10.1111/bju.16558}
}
EUVIMED